British Biotech has announced that it has dropped two drugs from itsportfolio, which were being developed in collaboration with Switzerland's Serono and aimed to research metalloenzyme inhibitors to fight inflammatory disease, following problems related to development.
The failure of the collagenase inhibitor BB-2827 for the treatment of rheumatoid arthritis, which entered clinical trials last year (Marketletter October 23, 2000), was the biggest loss for the company after it was found to have serious side effects. The other casualty was BB-76163 for the treatment of multiple sclerosis, which failed to prove effective in pre-clinical tests.
However, despite this disappointing news, the company is due to begin intermediate Phase II clinical trials for E21R, which is being developed in collaboration with Australia's BresaGen for the treatment of acute myeloid leukemia, and BB-10901 progression is continuing with Biocompatibles International, through Phase I/II clinical trials as a treatment for small cell lung cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze